Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Carter Kirk

Cornea and External Diseases Specialist River Forest, IL Medical Doctor

NPI 1083979181 CMS profile 1162960

7427 Lake St, River Forest, IL 60305

Open in the dashboard

General payments

$3,591

132 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$20,000 paid to institutions, not to them · program years 2024–2025

Through program year 2025, Carter Kirk of River Forest, IL is reported in the CMS Open Payments database as having received $3,591 across 132 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $20,000 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 70th percentile of Cornea and External Diseases Specialist profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $729 29
2024 General $641 25
2023 General $729 27
2022 General $505 17
2021 General $524 16
2020 General $121 7
2019 General $341 11

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Carter Kirk
  • Cornea and External Diseases Specialist median
  • Middle half of Cornea and External Diseases Specialist
  • National median

In program year 2025, general payments to Carter Kirk were reported at $729. Among 290 Cornea and External Diseases Specialist profiles paid that year, the median was $477 and the middle half received between $193 and $1,174.

Show as a table
Year Carter Kirk Cornea and External Diseases Specialist median Middle half National median
2019 $341 $276 $111–$734 $163
2020 $121 $146 $48–$330 $114
2021 $524 $254 $116–$566 $132
2022 $505 $251 $106–$729 $149
2023 $729 $344 $149–$759 $160
2024 $641 $366 $170–$927 $164
2025 $729 $477 $193–$1,174 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Johnson & Johnson Surgical Vision, Inc. $569 8 payments
  2. Novartis Pharmaceuticals Corporation $444 23 payments
  3. Alcon Vision LLC $403 12 payments
  4. Bausch & Lomb Americas Inc. $389 16 payments
  5. Harrow Eye, LLC $263 10 payments
  6. Tarsus Pharmaceuticals, Inc. $212 7 payments
  7. RxSight Inc $187 5 payments
  8. Eyevance Pharmaceuticals LLC $182 10 payments
  9. AbbVie, Inc. $165 8 payments
  10. Allergan Inc. $157 6 payments
  11. Other $621 27 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $3,591 132 payments
Products named General payments · program years 2019–2025
  1. XIIDRA $433 22 payments
  2. MIEBO $231 12 payments
  3. VEVYE $215 8 payments
  4. XDEMVY $212 7 payments
  5. RXSIGHT LIGHT DELIVERY DEVICE (LDD) $187 5 payments
  6. RXSIGHT CONTACT LENS $187 5 payments
  7. LIGHT ADJUSTABLE LENS (LAL) $187 5 payments
  8. RXSIGHT INJECTOR CARTRIDGE $187 5 payments
  9. RXSIGHT INJECTOR HANDPIECE $187 5 payments
  10. Wavelight $164 1 payment
  11. Other $2,327 86 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 23 drugs

Part D claims

1,411

Median for Ophthalmology: 891

Drug cost

$256,888

Median for Ophthalmology: $68,233

Branded share of claims

38.5%

Median for Ophthalmology: 29.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Restasis Cyclosporine Brand 70 $74,486
Xiidra Lifitegrast Brand 59 $65,824
Xdemvy Lotilaner Brand 15 $27,902
Miebo Perfluorohexyloctane/Pf Brand 22 $18,894
Lumigan Bimatoprost Brand 27 $18,206
Cyclosporine Generic 40 $16,616
Prednisolone Acetate Generic 140 $5,825
Latanoprost Generic 449 $5,700
Brimonidine Tartrate-Timolol Brimonidine Tartrate/Timolol Brand 31 $5,294
Lotemax Sm Loteprednol Etabonate Brand 11 $2,853

The 10 drugs with the highest cost, of 23 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,260 Part D prescribers listed as Ophthalmology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 39 billing codes

Paid by Medicare

$268,445

Medicare's payments for the services billed

Medicare patients

920

Average age 76

Services billed

2,817

572 women, 348 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 72%
Arthritis 46%
Diabetes 31%
Ischemic heart disease 26%
Chronic kidney disease 20%
Osteoporosis 19%
Heart failure 17%
Cancer 17%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 8 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
VEVYE
  • Harrow Eye, LLC $106
$106 — —
XDEMVY
  • Tarsus Pharmaceuticals, Inc. $85
$85 15 —
LUMIGAN
  • AbbVie, Inc. $40
$40 27 —
MIEBO
  • Bausch & Lomb Americas Inc. $37
$37 22 —
Cequa
  • Sun Pharmaceutical Industries Inc. $30
$30 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 8 in the dashboard with a free account

Records

132 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Cornea and External Diseases Specialist in Illinois

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record